Allarity Therapeutics reported a net loss of $11.2 million for the year ended December 31, 2025, a sharp improvement from the $25.1 million loss recorded in 2024. Revenue of $320 thousand was generated, the first revenue figure for the company since it had no sales in 2024. The company’s cash balance fell to $14.7 million, down from $19.5 million at the end of 2024, while total liabilities decreased to $8.4 million from $10.8 million, reflecting a modest reduction in debt and other obligations.
Research and development expenses rose to $6.6 million, up from $6.1 million in 2024, as Allarity accelerated clinical work on its lead asset, stenoparib. General and administrative costs fell sharply to $6.3 million, a 45 percent reduction from $11.4 million in 2024, driven by a deliberate focus on cost control amid intensified clinical development. The combination of higher R&D spending and lower G&A helped narrow the net loss, illustrating the company’s effort to balance investment in science with disciplined operating expenses.
Allarity’s clinical portfolio continues to advance. The company launched a new Phase 2 protocol for stenoparib in platinum‑resistant ovarian cancer, designed to refine dosing and incorporate the proprietary Drug Response Predictor (DRP®) platform for patient selection. In addition, a combination study with temozolomide in recurrent small‑cell lung cancer was initiated, expanding the potential therapeutic reach of stenoparib. These milestones support the company’s Fast Track designation from the FDA, a regulatory tailwind that could accelerate review and approval if clinical data remain favorable.
In March 2026, Allarity closed a $20 million debt financing that extends its cash runway into mid‑2028. The infusion of capital, combined with the improved loss profile and reduced liabilities, positions the company to sustain its clinical program over the next 12 months. Nonetheless, the company remains in a net‑loss position and will need additional capital to fund a planned Phase 3 trial, underscoring ongoing financial risk despite the recent tailwinds.
Allarity’s 2025 results demonstrate a clear trajectory toward financial stabilization while maintaining momentum in its key clinical programs. The company’s ability to reduce operating expenses, secure additional financing, and advance stenoparib through critical development stages signals a strategic focus on achieving regulatory milestones and preparing for eventual commercialization.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.